Achillion Pharmaceuticals (NASDAQ:ACHN) announces results from their Phase 1 multiple ascending dose study with ACH-5228 outside U.S.
43 healthy volunteers were enrolled in the study. Subjects received oral doses ranging from 40 mg to 200 mg twice a day (BID) for 14 days.
The results demonstrated that ACH-5228, when dosed 120 mg BID or higher, achieved near complete and sustained Alternative Pathway inhibition with a mean value of >95% at steady state concentrations.
ACH-5228 was well tolerated over the dose ranges, which include the doses expected to be evaluated in Phase 2 trials.
The Company expects to submit an IND application in Q4 2019.
Shares are up 3% premarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.